

Mar Infante · Mercedes Durán
Eva Esteban-Cardenaosa · Cristina Miner
Eladio Velasco

High proportion of novel mutations of *BRCA1* and *BRCA2* in breast/ovarian cancer patients from Castilla-León (central Spain)

Received: 30 January 2006 / Accepted: 12 March 2006 / Published online: 7 June 2006
© The Japan Society of Human Genetics and Springer-Verlag 2006

Abstract A total of 264 unrelated breast/ovarian cancer patients and 45 healthy individuals with familial antecedents referred for genetic testing were scanned for germ-line mutations in *BRCA1* and *BRCA2* by conformation-sensitive gel electrophoresis (CSGE) and heteroduplex analysis by capillary array electrophoresis (HA-CAE). We detected 101 distinct mutations (41 in *BRCA1* and 60 in *BRCA2*); ten of them have not been previously reported. These mutations were c.2411_2429dup19, c.2802_2805delCAAA and c.5294A>G (p.E1725E) of *BRCA1*; and c.667C>T (p.Q147X), c.2683C>T (p.Q819X), c.5344_5347delATA, c.5578_5579delAA;insT, c.8260_8261insGA, c.744+14C>T and c.8099A>G (p.Y2624C) of *BRCA2*. Twenty-four different mutations, including seven of the new mutations (five frameshift and two nonsense), were classified as pathogenic. These 24 alterations were found in 39 families (12.6% of all families). A remarkable proportion of deleterious mutations were found in *BRCA2*: 25 families carried a mutation in *BRCA2* (*BRCA2*+; 64.1%) compared with 14 families *BRCA1*+ (35.9%). The highest incidences of deleterious mutations were found in families with three or more cases of site-specific breast cancer (BC) (27.4%) and families with BC and ovarian cancer (22.2%). Finally, four recurrent mutations, 3036_3039delACAA, c.5374_5377delTATG of *BRCA2*, as well as c.5272-

1G>A and c.5242C>A (p.A1708E) of *BRCA1*, accounted for 44% of all of the deleterious mutations.

Keywords *BRCA1* · *BRCA2* · Breast cancer · Ovarian cancer · Heteroduplex analysis · Capillary electrophoresis · Deleterious mutations

Introduction

Breast cancer (BC) is the most common malignancy among women in industrialized countries. It is estimated that 5–10% of all BCs are due to genetic predisposition. Mutations in the tumor-suppressor genes *BRCA1* (MIM#113705) and *BRCA2* (MIM#600185) confer an increased risk of developing BC and ovarian cancer (OC) (Ford et al. 1998). However, mutations in both genes only explain approximately 20% of families with evidence of inherited susceptibility to breast cancer (Wooster and Weber 2003). Disease-causing mutations are distributed throughout the entire coding regions of both genes (The BIC database: <http://www.research.nhgri.nih.gov/bic/Member/index.shtml>). Apart from specific ethnic groups, there are no predominant mutations accounting for the majority of inherited breast cancer cases, and deleterious mutations present significant ethnic and geographic variation. Since the identification of *BRCA1* and *BRCA2* as the principal genes responsible for inherited breast cancer (Miki et al. 1994; Tavtigian et al. 1996), more than 3,400 distinct DNA sequence variants have been described in the BIC database, of which 1,723 can be classified as pathogenic, including 1,422 truncating mutations (1,064 frameshift and 358 nonsense) and 301 splicing alterations. The remaining mutations, including 1,346 distinct missense changes, are unclassified variants of uncertain clinical consequences.

With a view to offering genetic counseling to BC and OC patients from Castilla y Leon (Spain), we have scanned the entire coding regions and the exon–intron boundaries of *BRCA1* and *BRCA2*. In previous reports

M. Infante · M. Durán · E. Esteban-Cardenaosa
C. Miner · E. Velasco (✉)
Laboratorio de Genética del Cáncer, Instituto de Biología y Genética Molecular, Universidad de Valladolid,
Sanz y Forés s/n, 47003 Valladolid, Spain
E-mail: evelasco@ped.uva.es
Tel.: +34-9831-84809
Fax: +34-9831-84800

E. Esteban-Cardenaosa
Laboratorio de Biología Molecular,
Departamento de Biopatología Clínica,
Hospital La Fé, Valencia, Spain

we showed that our BC/OC patients had a wide range of mutations (Velasco-Sampedro et al. 2002; Duran et al. 2003; Diez et al. 2003). In fact, we had already identified a total of 27 novel DNA changes, illustrating the high diversity of *BRCA1/2* mutations in our population (Velasco-Sampedro et al. 2002; Duran et al. 2003; Velasco et al. 2005).

Here we present the mutation-detection data corresponding to a set of 309 families analyzed by conformation-sensitive gel electrophoresis (CSGE) and heteroduplex analysis with capillary array electrophoresis (HA-CAE), the new high-throughput method developed by our group (Esteban-Cardenosa et al. 2004). As result of this work, we describe for the first time seven deleterious mutations (two of *BRCA1* and five of *BRCA2*), one *BRCA2* missense mutation, and two polymorphic variants (one in each *BRCA* gene).

Patients and methods

Patients

Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood samples as well as written informed consent were received from 264 unrelated BC/OC patients and 45 healthy individuals with familial antecedents. BC/OC patients were classified into groups based on the following criteria:

- I. One BC before the age of 40 (67 families)
- II. Two BCs in the same family before the age of 50 (33 families)
- III. Three or more cases of BC in the same family (62 families)
- IV. BC and OC in the same family or patient (27 families)
- V. One male BC (14 families)
- VI. Bilateral BC (30 families)
- VII. Two OCs (no families)
- VIII. One BC plus familial aggregation of other types of cancer (four families)

Additionally, 27 unrelated BC patients of unknown familial antecedents also participated (no relatives with BC or OC were available). Finally, 125 relatives of individuals with deleterious mutations or unclassified variants were also studied. DNA from all samples was extracted using the QIAampDNA Blood mini kit (Qiagen, Hilden, Germany).

BRCA1 and *BRCA2* mutational analysis

Seventy-three PCR fragments (31 for *BRCA1* and 42 for *BRCA2*) were amplified in 23 multiplex PCR groups. Thermocycling conditions were performed in a GeneAmp PCR system 9700 as described before (Esteban-Cardenosa et al. 2004). The mutation-detection method was either standard CSGE (92 families) (Ganguly et al.

1993; Cebrian et al. 2002) or fluorescent HA-CAE (217 families) in an ABI3100 DNA sequencer (Applied Biosystems) (Esteban-Cardenosa et al. 2004). In this case, one primer of each pair of the PCR reactions was fluorescently labeled with FAM, HEX or NED.

DNA sequencing

Fragments showing a CSGE- or HA-CAE-altered pattern were sequenced with the BigDye Terminator Sequencing Kit v3.1 (Applied Biosystems) with unlabeled forward and reverse primers.

Mutation nomenclature

Nucleotide positions were numbered considering the cDNA reference sequences U14680 (*BRCA1*) and U43746 (*BRCA2*). Description of mutations was according to accepted nomenclature guidelines of the Human Genome Variation Society (<http://www.genomic.unimelb.edu.au/mdi/mutnomen/>).

Results and discussion


Novel mutations

The mutational analysis of *BRCA1* and *BRCA2* by CSGE and HA-CAE (Fig. 1) revealed a total of 101 different mutations, 41 in *BRCA1* and 60 in *BRCA2*, in 309 families (Tables 1 and 2). Ten novel mutations were characterized, including five frameshift (two deletions, one insertion, one duplication and one combined deletion/insertion mutation) and two nonsense mutations (Table 1), as well as one missense, one synonymous and one intronic variant mutation (Table 2). These new mutations were c.2802-2805delCAAA, c.2411-2429dup19 and c.5294 A > G (p.E1725E) of *BRCA1*; and c.667C > T (p.Q147X), c.2683C > T (p.Q819X), c.5344-5347delAATA, c.5578-5579delAA;insT, c.8260_8261insGA, c.744+14C > T and c.8099A > G (p.Y2624C) of *BRCA2*. Together with our previous results (Velasco-Sampedro et al. 2002; Duran et al. 2003; Diez et al. 2003; Velasco et al. 2005), novel mutations represent 29% (37 out of 128 different DNA changes detected in 459 unrelated families) of all mutations identified, thus illustrating the high variability of the *BRCA* genes.

Pathological mutations

Twenty-four different disease-causing mutations (9 in *BRCA1* and 15 in *BRCA2*) were identified in 39 unrelated families (12.6% of all the families), including seven of the novel mutations, which create premature stop

Fig. 1 Examples of heteroduplex analysis by capillary array electrophoresis (HA-CAE) patterns. Novel pathogenic mutations c.5344_5347delAATA from *BRCA2* exon fragment 11R labeled with FAM and c.2683C>T (p.Q819X) from *BRCA2* exon fragment 11D labeled with NED are shown (Esteban-Cardenosa et al. 2004). Sizes of DNA standard Genescan 500-ROX are indicated



codons, truncating the *BRCA* proteins (Table 1). Taking into account the previous description of another total of 11 different new pathogenic mutations have been exclusively identified in our patients, indicating that each four novel truncating mutations (Duran et al. 2003), a population will show a specific mutational spectrum.

Table 1 Pathogenic mutations of *BRCA1* and *BRCA2*. Novel mutations are marked with an *asterisk*

Exon	Mutation	Effect	Type of mutation	No. of families ^{a,b}	Criteria of patients ^c	BIC no.
<i>BRCA1</i>						
5	c.330A>G	22 bp-deletion	Splicing	1 (3)	III	1944
5	c.331+1G>A		Splicing	1 (2)	IV	2843
11	c.2360delC	STOP 752	Frameshift	1 (1)	IV	2951
11	c.2411-2429dup19*	STOP 773	Frameshift	1 (1)	III	New
11	c.2508-2509delGA	STOP 799	Frameshift	1 (1)	III	9337
11	c.2802_2805delCAAA*	STOP 998	Frameshift	1 (1)	III	New
11	c.3889_3890delAG	STOP 1265	Frameshift	1 (1)	H (IV)	2384
18	c.5242C>A	p.A1708E	Missense	3 (4)	VI/ n.d./VI	1147
19	c.5272-1G>A	Exon 19 skipping	Splicing	4 (5)	II/II/III/VI-I	3942
Total				14 (19)		
<i>BRCA2</i>						
5	c.667C>T*	p.Q147X	Nonsense	1 (1)	III	New
11	c.2683C>T*	p.Q819X	Nonsense	1 (1)	IV	New
11	c.3036_3039delACAA	STOP 958	Frameshift	7 (11)	I/III/IV/H (I)/III/n.d./III	1021
11	c.3492insT	STOP 1098	Frameshift	1 (2)	III	2067
11	c.4150G>T	p.E1308X	Nonsense	1 (2)	I	2480
11	c.5164_5167delGAAA	STOP 1668	Frameshift	1 (1)	III	2627
11	c.5344_5347delAATA*	STOP 1710	Frameshift	2 (2)	I / IV	New
11	c.5374_5377delTATG	STOP 1723	Frameshift	3 (5)	H (I)/III/III	Duran et al. (2003)
11	c.5578_5579delAA; insT*	STOP 1790	Frameshift	1 (1)	III	New
11	c.6126delT	STOP 2003	Frameshift	1 (3)	IV	Duran et al. (2003)
11	c.6503_6504delTT	STOP 2099	Frameshift	1 (1)	V	1047
11	c.6884C>G	p.S2219X	Nonsense	1 (2)	II	1054
18	c.8260_8261insGA*	STOP 2694	Frameshift	1 (1)	H (II)	New
23	c.9254_9258delATCAT	STOP 3015	Frameshift	2 (2)	III/III	1073
25	c.9538_9539delAA	STOP 3109	Frameshift	1 (3)	III	1422
Total				25 (38)		

^aIn parenthesis is indicated the number of times the mutation has been identified in our entire set of breast cancer patients (459 unrelated patients), including previous studies

^bIn previous studies (Velasco-Sampedro et al. 2002; Duran et al. 2003; Diez et al. 2003), we reported seven additional deleterious mutations that were not found in the present work: c.1135insA (one family), c.3958_3962del5;ins4 (one family), c.5236G>A (p.G1706E) (one family) and c.5396+1G>A (one family) from *BRCA1*; and c.1538_1541delAAGA (two families), c.7288C>T (p.Q2354X) (one family), and c.9476A>T (p.K3083X) (one family) from *BRCA2*. Therefore, the final number of independent families with mutations in *BRCA1* and *BRCA2* was 23 and 42, respectively

^cSelection criteria I–VIII; see text for definitions. *n.d.* No data, *H* healthy individuals with familial antecedents in parenthesis. One patient carrying mutation c.5272-1G>A met both criteria I and VI (criterion VI–I)

Table 2 List of polymorphisms and unclassified variants of *BRCA1* and *BRCA2* detected in 309 families. Novel DNA variants are denoted with an *asterisk*

DNA change (amino acid change)	Exon	Frequency ^a	Type of mutation	Effect ^b	BIC no. or reference
<i>BRCA1</i>					
c.101-115T>C	I-1	0.23	Intronic variant	Pol.	Velasco-Sampedro et al. (2002)
c.233G>A (p.K38K)	3	1	Synonymous	Pol.	1317
c.561-34 T>C	I-7	0.19	Intronic variant	Pol.	1424
c.667-58delT	I-8	0.32	Intronic variant	Pol.	1322
c.710C>T (p.C197C)	9	0.02	Synonymous	Pol.	1237
c.1186A>G (p.Q356R)	11	0.06	Missense	Pol.	1014
c.1605C>T (p.R496C)	11	1	Missense	U.V.	2294
c.2121C>T (p.L668F)	11	1	Missense	U.V.	2313
c.2196G>A (p.D693N)	11	0.05	Missense	Pol.	1045
c.2201 C>T (p.S694S)	11	0.22	Synonymous	Pol.	1047
c.2430T>C (p.L771L)	11	0.22	Synonymous	Pol.	1055
c.2640C>T (p.R841W)	11	1	Missense	U.V.	1392
c.2731C>T (p.P871L)	11	0.24	Missense	Pol.	1067
c.3232A>G (p.E1038G)	11	0.23	Missense	Pol.	1087
c.3238G>A (p.S1040N)	11	8	Missense	Pol.	1089
c.3537A>G (p.S1140G)	11	1	Missense	U.V.	1790
c.3667A>G (p.K1183R)	11	0.28	Missense	Pol.	1099
c.3954G>C (p.A1279P)	11	1	Missense	U.V.	Velasco et al. (2005)
c.4427T>C (p.S1436S)	13	0.18	Synonymous	Pol.	1128
c.4476 + 45insT	I-13	1	Intronic variant	Pol.	Velasco et al. (2005)
c.4477-10C>T	I-13	1	Intronic variant	Pol.	2419
c.4604-63C>G	I-14	0.18	Intronic variant	Pol.	4234
c.4654G>T (p.S1512I)	15	2	Missense	Pol.	1136
c.4719G>A (p.V1534M)	15	2	Missense	U.V.	1850
c.4956A>G (p.S1613G)	16	0.18	Missense	Pol.	1140
c.5075G>A (p.M1652I)	16	2	Missense	Pol.	1143
c.5193 + 6 C>G	I-17	1	Intronic variant	U.V.	6643
c.5194-53C>T	I-17	0.04	Intronic variant	Pol.	Velasco-Sampedro et al. (2002)
c.5271 + 66G>A	I-18	0.24	Intronic variant	Pol.	1387
c.5294 A>G (p.E1725E)*	19	1	Synonymous	Pol.	New
c.5396 + 47dup	I-20	3	Intronic variant	Pol.	1425
c.5586 + 35T>A	I-23	1	Intronic variant	Pol.	Velasco et al. (2005)
<i>BRCA2</i>					
c.203G>A 2 (5'UTR)	2	0.25	5'UTR	Pol.	1666
c.296-7T>A	I-2	1	Intronic variant	Pol.	2741
c.353 A>G (p.Y42C)	3	1	Missense	U.V.	1209
c.451G>C (p.A75P)	3	1	Missense	U.V.	1211
c.744 + 14 C>T*	I-6	1	Intronic variant	Pol.	New
c.744 + 21A>T	I-6	1	Intronic variant	Pol.	Velasco et al. (2005)
c.744 + 93C>T	I-6	1	Intronic variant	Pol.	Velasco et al. (2005)
c.745-19 C>T	I-6	1	Intronic variant	Pol.	2164
c.860-16A>C	I-7	1	Intronic variant	Pol.	3996
c.909 + 56C>T	I-8	0.02	Intronic variant	Pol.	2411
c.1093A>C (p.N289H)	10	0.02	Missense	Pol.	1129
c.1155 A>G (p.S309S)	10	1	Synonymous	Pol.	Velasco et al. (2005)
c.1342C>A (p.H372N)	10	0.23	Missense	Pol.	1668
c.1593A>G (p.S455S)	10	2	Synonymous	Pol.	1106
c.1991A>G (p.N588S)	10	1	Missense	U.V.	Velasco et al. (2005)
c.2137 + 22delT	I-10	0.5	Intronic variant	Pol.	2416
c.2353C>G (p.L709V)	11	1	Missense	U.V.	5192
c.3031G>A (p.D935N)	11	1	Missense	U.V.	1255
c.3111G>A (p.Q961Q)	11	1	Synonymous	Pol.	1901
c.3199A>G (p.N991D)	11	0.11	Missense	Pol.	1903
c.3624A>G (p.K1132K)	11	0.15	Synonymous	Pol.	1661
c.4035T>C (p.V1269V)	11	0.06	Synonymous	Pol.	1662
c.4296 G>A (p.L1356L)	11	4	Synonymous	Pol.	3525
c.4486G>T (p.D1420Y)	11	1	Missense	Pol.	1273
c.4926C>T (p.T1566T)	11	2	Synonymous	Pol.	Velasco et al. (2005)
c.5972C>T (p.T1915M)	11	0.01	Missense	Pol.	1108
c.6110G>A (p.S1961N)	11	1	Missense	U.V.	6449
c.6328C>T (p.R2034C)	11	4	Missense	Pol.	1325
c.7365A>G (p.G2379G)	14	1	Synonymous	Pol.	Velasco-Sampedro et al. (2002)
c.7470A>G (p.S2414S)	14	0.01	Synonymous	Pol.	1125
c.7625 C>T (p.A2466V)	14	1	Missense	Pol.	1365
c.7663 + 53C>T	I-14	1	Intronic variant	Pol.	2738

Table 2 Continued

DNA change (amino acid change)	Exon	Frequency ^a	Type of mutation	Effect ^b	BIC no. or reference
c.8034-14T>C	I-16	0.38	Intronic variant	Pol.	1126
c.7987C>T (p.L2587F)	16	1	Missense	U.V.	Velasco et al. (2005)
c.8099 A>G (p.Y2624C)*	17	1	Missense	U.V.	NEW
c.8222A>G (p.D2665G)	18	1	Missense	U.V.	1382
c.8410G>A (p.V2728I)	18	2	Missense	U.V.	1385
c.8559-63_65delGAT	I-18	1	Intronic variant	Pol.	Velasco et al. (2005)
c.9078G>T (p.K2950N)	22	1	Missense	U.V.	1405
c.9225G>A (p.L2999L)	23	1	Synonymous	Pol.	4527
c.9603C>G (p.L3125L)	25	1	Synonymous	Pol.	Velasco-Sampedro et al. (2002)
c.9729 + 143A>T	I-25	1	Intronic variant	Pol.	Velasco-Sampedro et al. (2002)
c.10204A>T (p.K3326X)	27	2	Nonsense	Pol.	1179
c.10462A>G (p.I3412V)	27	3	Missense	Pol.	1452
c.10338 G>A (p.R3370R)	27	1	Synonymous	Pol.	2729

^aFrequencies below 0.01 are indicated as number of times the mutation was identified in this set of patients

^bPol Polymorphism, U.V. unclassified variant

The two new frameshift mutations of *BRCA1*, c.2411_2429dup19 and c.2802_2805delCAAA, took place in exon 11. Both were detected in families with more than three BC cases (group III). With regard to *BRCA2*, the novel two nonsense mutations, p.Q147X and p.Q819X, and three frameshift mutations, c.5344_5347delAATA (two families), c.5578_5579de-IAA;insT and c.8260_8261ins GA, were identified in exons 5, 11 and 18. These five mutations were found in six unrelated patients of families of criteria groups I, III (two families), IV (two families), and one healthy individual with two familial antecedents with BC (c.8260_8261ins GA).

BRCA1/BRCA2 ratio of pathogenic mutations

We have found 14 unrelated *BRCA1*+ families (35.9%) and 25 *BRCA2*+ families (64.1%). When taking into account our previous results (Velasco-Sampedro et al. 2002; Duran et al. 2003; Diez et al. 2003), the final *BRCA1/BRCA2* ratio did not change, with 23 and 42 deleterious mutations in *BRCA1* (35.4%) and *BRCA2* (64.6%), respectively (Table 1). A previous study of the Spanish Breast Cancer Consortium, which comprised families from our first five selection criteria (Diez et al. 2003), did not show significant differences between *BRCA1* and *BRCA2* (53% *BRCA1*+ versus 47% *BRCA2*+).

Apart from a putative specific feature of our population, there are several alternative reasons for this *BRCA1/BRCA2* imbalance. First, a majority of *BRCA2* deleterious mutations (one *BRCA1*+ versus six *BRCA2*+) were reported in young Spanish BC women from the Mediterranean area (Martinez-Ferrandis et al. 2003). Our data support these results, but only three pathogenic mutations have been found in group I.

One additional explanation may be an underrepresentation of families with BC and OC, group IV (only 8.7% of our families), where mutations in *BRCA1* are more frequent than in *BRCA2* (Risch et al. 2001).

Moreover, a higher incidence of *BRCA2* mutations has been previously reported in Japanese site-specific BC families (our group III) (Ikeda et al. 2001). In fact, we have found 5 *BRCA1*+ families and 12 *BRCA2*+ families in group III.

Another cause may be a high frequency of *BRCA1* rearrangements, which are undetectable by traditional PCR-based mutation detection methods such as CSGE and SSCP. However, this possibility has been recently excluded, as only three patients carried this sort of mutations (data not shown).

Finally, another possibility is the absence of the most prevalent mutation of *BRCA1* in Spain, c.187_188de-IAAG of Ashkenazi Jews (Diez et al. 1998, 2003) and the abundance of recurrent mutations of *BRCA2* in our population. This effect has been previously reported in Iceland, where a single *BRCA2* frameshift mutation, c.999del5, accounts for 40% of male BCs and 7% of female BCs (Tulinius et al. 2002). The most prevalent mutation was c.3036_3039delACAA of *BRCA2*, which was found in seven families in this study. In addition, it was detected in other four families in a preceding report (Duran et al. 2003), making a total of 11 unrelated families. This 4-bp deletion is also the most frequent *BRCA2* mutation in Spain (Diez et al. 2003; Salazar et al. 2005), and it has been detected in many European countries (Neuhausen et al. 1998). Other important recurrent mutations of *BRCA2* were c.5374_5377del-TATG, c.6126delT and c.9538_9539delAA (Table 1). These mutations represent more than one-third of all pathogenic mutations and may be founder mutations in our population, although this point has to be corroborated. Probably, the combination of all these hypotheses may explain the *BRCA1/BRCA2* imbalance of our BC/OC patients.

The most frequent *BRCA1* mutations were c.5272-1G>A and the missense mutation c.5242C>A (p.A1708E, Table 1) whose pathogenicity has been previously demonstrated (Vallon-Christersson et al. 2001). These two alterations are responsible for 39% of all deleterious mutations of *BRCA1*. Concerning

the mutation c.5272-1G>A, it was found five times in our complete cohort of BC patients, but it has also been detected in one sporadic BC case without known familial history, who was diagnosed at 54 years of age (data not shown). This DNA change is relatively rare in the BIC database (only three records in Western European and Spanish populations). Therefore, these data also suggest a putative founder effect in Spain, which has not been demonstrated yet. Finally, the third most common mutation of *BRCA1* (three unrelated families, Table 1) is the splicing mutation c.330A>G (r.310_331del22) of Galician origin (Vega et al. 2001), which was detected only once in this cohort of 309 families.

Frequency of mutations by selection criteria

The distribution of deleterious mutations according to the selection criteria was 3/67 (4.5%) in group I, 3/33 (9.1%) in group II, 17/62 (27.4%) in group III, 6/27 (22.2%) in group IV, 1/14 in group V, 3/30 (10%) in group VI, 2/27 (7.4%) in BC patients with unknown familial history and 4/45 in healthy individuals with familial antecedents with BC. No mutations were found in groups VII (two ovarian cancers) and VIII (BC + familial aggregation). As expected, a great proportion of mutations were identified in patients from groups III and IV (59% of all mutations), as they showed the highest ratio of cancer-prone mutations (27.4 and 22.2%, respectively). This frequency of mutations by clinical group is similar to the results previously reported in the Spanish population (Diez et al. 2003).

Unclassified variants and polymorphisms

The vast majority of mutations, 77 variants (32 of *BRCA1* and 45 of *BRCA2*, Table 2), could not be classified as pathogenic mutations. As previously reported in other populations (Katagiri et al. 1998), missense variants outweighed deleterious mutations (34 versus 24). Fifty-nine DNA changes were considered as mere polymorphisms, including the two novel variants c.5294A>G of *BRCA1* and c.744+14C>T of *BRCA2* (Table 2). The remaining 18 mutations (17 missense mutations and one intronic variant) were variants of unknown physiological effect or unclassified variants, including the novel missense mutation c.8099A>G (p.Y2624C), which affected a conserved residue of *BRCA2* (Table 2). Unfortunately, familial segregation could not be performed as this patient belongs to the group of young patients without known familial antecedents. Although a great number of the 1,346 different missense mutations (one in four codons of the *BRCA* genes has a missense mutation) may presumably be related to the disease, they should be regarded as unclassified variants since a functional assay of the *BRCA* proteins is still not available. Therefore, the role of these

unclassified missense mutations in BC and OC remains to be elucidated. Despite a comprehensive analysis of *BRCA1* and *BRCA2*, there will be high-risk BC families without deleterious mutations in these genes. In fact, the cumulative evidence from several studies suggests the putative influence of additional moderate or high penetrance genes (Nathanson and Weber 2001). Their characterization will contribute to clarifying the spectrum of genes involved in familial BC.

Acknowledgements This work has been supported by the Junta de Castilla y León through the regional Breast Cancer Prevention Program. M. Infante and E. Esteban-Cardenosa were recipients of fellowships from the "Fundación Burgos para la Investigación en Salud." We are also grateful to the patients and the clinicians, especially Dr. García Girón and Dr. Lastra (Hospital General Yagüe, Burgos, Spain), who collaborated in this study.

References

- Cebrian A, Ruiz-Llorente S, Cascon A, Osorio A, Martínez-Delgado B, Benítez J, Robledo M (2002) A rapid and easy method for multiple endocrine neoplasia type 1 mutation detection using conformation-sensitive gel electrophoresis. *J Hum Genet* 47:190–195
- Diez O, Domenech M, Alonso MC, Brunet J, Sanz J, Cortes J, del Rio E, Baiget M (1998) Identification of the 185delAG *BRCA1* mutation in a Spanish Gypsy population. *Hum Genet* 103:707–708
- Diez O, Osorio A, Duran M, Martínez-Ferrandis JI, de la Hoya M, Salazar R, Vega A, Campos B, Rodríguez-Lopez R, Velasco E, Chaves J, Díaz-Rubio E, Jesus Cruz J, Torres M, Esteban E, Cervantes A, Alonso C, San Roman JM, Gonzalez-Sarmiento R, Miner C, Carracedo A, Eugenia Armengod M, Caldes T, Benítez J, Baiget M (2003) Analysis of *BRCA1* and *BRCA2* genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. *Hum Mutat* 22:301–312
- Duran M, Esteban-Cardenosa E, Velasco E, Infante M, Miner C (2003) Mutational analysis of *BRCA2* in Spanish breast cancer patients from Castilla-Leon: identification of four novel truncating mutations. *Hum Mutat* 21:448
- Esteban-Cardenosa E, Duran M, Infante M, Velasco E, Miner C (2004) High-throughput mutation detection method to scan *BRCA1* and *BRCA2* based on heteroduplex analysis by capillary array electrophoresis. *Clin Chem* 50:313–320
- Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struwing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the *BRCA1* and *BRCA2* genes in breast cancer families. *Am J Hum Genet* 62:676–689
- Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. *Proc Natl Acad Sci USA* 90:10325–10329
- Ikeda N, Miyoshi Y, Yoneda K, Shiba E, Sekihara Y, Kinoshita M, Noguchi S (2001) Frequency of *BRCA1* and *BRCA2* germline mutations in Japanese breast cancer families. *Int J Cancer* 91:83–88
- Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, Abe R, Tsuchiya A, Sugano M, Takai S, Yoneda M, Fukutomi T, Nanba K, Makita M, Okazaki H, Hirata K, Okazaki M, Furutsuma Y, Morishita Y, Iino Y, Karino T, Ayabe H, Hara S,

- Kajiwaru T, Houga S, Shimizu T, Toda M, Yamazaki Y, Uchida T, Kunitomo K, Sonoo H, Kurebayashi J, Shimotsu K, Nakamura Y, Miki Y (1998) High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. *J Hum Genet* 43:42–48
- Martinez-Ferrandis JI, Vega A, Chirivella I, Marin-Garcia P, Insa A, Lluch A, Carracedo A, Chaves FJ, Garcia-Conde J, Cervantes A, Armengod ME (2003) Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early-onset breast cancer: identification of three novel pathogenic mutations. *Hum Mutat* 22:417–418
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266:66–71
- Nathanson KL, Weber BL (2001) 'Other' breast cancer susceptibility genes: searching for more Holy Grail. *Hum Mol Genet* 10:715–720
- Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, Ponder BAJ, Weber B, Devilee P, Borg A, Narod SA, Goldgar D (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. *Am J Hum Genet* 62:1381–1388
- Osorio A, Robledo M, Albertos J, Diez O, Alonso C, Baiget M, Benitez J (1998) Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer families. *Cancer Lett* 123:153–158
- Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JLA, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 68:700–710
- Salazar R, Cruz-Hernandez JJ, Sanchez-Valdivieso E, Rodriguez CA, Gomez-Bernal A, Barco E, Fonseca E, Portugal T, Gonzalez-Sarmiento R (2006) BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain. *Cancer Lett* 233(1):172–177
- Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Jannecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE et al. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. *Nat Genet* 12:333–337
- Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugsdottir S, Eyfjord JE (2002) The effect of a single BRCA2 mutation on cancer in Iceland. *J Med Genet* 39:457–462
- Vallon-Christersson J, Cayan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Moller P, Kristofferson U, Olsson H, Borg A, Monteiro AN (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. *Hum Mol Genet* 10:353–360
- Vega A, Campos B, Bressac-de-Paillerets B, Bond PM, Janin N, Douglas FS, Domenech M, Baena M, Pericay C, Alonso C, Carracedo A, Baiget M, Diez O (2001) The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. *Hum Mutat* 17:520–521
- Velasco E, Infante M, Duran M, Esteban-Cardenosa E, Lastra E, Garcia-Giron C, Miner C (2005) Rapid mutation detection in complex genes by heteroduplex analysis with capillary array electrophoresis. *Electrophoresis* 26:2539–2552
- Velasco-Sampedro E, Esteban-Cardenosa E, Infante-Sanz M, Durán-Dominguez M, Lastra-Aras E, Garcia-Giron C, Miner-Pino C (2002) Molecular study of the BRCA1 and BRCA2 genes in 153 breast cancer families from Castilla y Leon (Spain): new nine unclassified variants identified. *Med Clin (Barc)* 119:441–445
- Wooster R, Weber BL (2003) Breast and ovarian cancer. *N Engl J Med* 348:2339–2347